Earnings call transcript: Globus Medical Q1 2026 beats forecasts, stock dips

Globus Medical delivered a strong Q1 2026 beat, with EPS of $1.12 versus $0.92 expected and revenue of $759.9 million versus $740.3 million expected, then raised full-year non-GAAP EPS guidance to $4.70-$4.80 from $4.40-$4.50. Gross margin improved to 69.2% adjusted from 67.3% a year ago, while management highlighted robust base-business growth, new product launches, and FDA 510(k) clearances. Shares still fell 4.65% after hours to $88.35, suggesting investors were focused on mix, Nevro volatility, or broader market sentiment despite the earnings beat.

Analysis

The market is still pricing Globus like a cyclical med-tech compounder, but the quarter argues for a re-rate toward a self-help margin story with multiple operating levers. The key second-order effect is that the company is now using scale to convert growth into durable free cash flow while still funding innovation, which materially lowers the probability that execution slips will translate into earnings compression. That makes the post-earnings selloff look more like a mismatch between headline top-line expectations and a still-evolving mix shift than a read-through on fundamentals.

The overlooked issue is mix. Management is intentionally trading some near-term revenue recognition in Enabling Technologies for higher attach rates downstream, which should benefit procedure economics, consumables, and service over the next 4-8 quarters even if it suppresses reported robot revenue in the near term. That creates an unusual setup where the street could underwrite too much 2026 revenue and too little 2027+ EBITDA, especially if the integration work on the acquired pain business continues to normalize late in the year.

Competitive dynamics remain favorable. If the installed base and rep density story is working, incumbents without equivalent procedural pull-through will have to spend more to defend accounts, which can pressure margins at the low end of the spine market. The biggest risk is not demand, but a delay in converting the new commercial model into visible recurring revenue; if that conversion lags into 2H, the stock can de-rate even with guide maintenance because investors will focus on the top-line cadence rather than the underlying unit economics.

Key Decisions for Investors

• Initiate a tactical long GMED into post-earnings weakness, targeting a 3-6 month horizon. Risk/reward is attractive if the market re-prices margin durability; downside is limited if the thesis is wrong because cash flow and buybacks provide support.
• Prefer GMED calls or call spreads over outright stock for the next 1-2 quarters. The thesis is a multiple expansion on evidence of margin conversion, while option premium caps risk if the Enabling Technologies mix shift temporarily slows reported growth.
• Pair long GMED vs short MDT over 2-4 months. GMED has clearer self-help, better margin momentum, and a more visible path to EPS upside; MDT is more exposed to slower operating leverage and a less compelling near-term catalyst mix.
• If you own GMED equity, hedge with a 2H26 revenue disappointment structure rather than a generic market hedge. Buy downside protection around the next guidance checkpoint, because the main risk is not earnings miss but guide fragility from deferred robot revenue recognition.
• Avoid chasing the implied move higher in the spine peer set until GMED demonstrates that the Enabling Technologies mix shift is accretive to procedural revenue. The better expression is to wait for confirmation of recurring revenue conversion, then add on a pullback.